Table 2.
Multilineage Engraftmenta
| TBI cGy | nb | % donor | % in donor (H2Kd+) lymphoid gate | ||||||
|---|---|---|---|---|---|---|---|---|---|
| αβ-TCR | CD8 | CD4 | B220 | DX5 | CD11c | Mac-1 | |||
| 300 | 7 | 22.5±6.5 | 16.7±7.9c | 2.7±1.3 | 13.6±6.3 | 78.2±8.4 | 10.0±3.8 | 1.4±0.37 | 4.2±0.46 |
| 200 | 7 | 18.4±5.4 | 7.6±3.0 | 1.2±0.62 | 6.2±1.6 | 88.0±2.3 | 7.9±4.7 | 0.77±0.58 | 3.4±0.95 |
| 100 | 5 | 3.1±1.0 | 9.9±6.4 | 1.1±0.28 | 9.1±8.3 | 81.1±9.2 | 4.3±3.4 | 0.91±0.58 | 5.5±3.0 |
a
Multilineage typing was performed in mice between 2 and 4 mo after BMT. Multi-lineage engraftment was assessed in 50 μl PB by four-color staining for FITC-conjugated anti-donor-specific antibody (H-2Kd) and different fluorochrome (PE, PerCP and APC)-conjugated lineage makers, including T-cells (anti-CD4, anti-CD8α, and anti-TCR-β), B-cells (anti-B220), NK-cells (anti-DX5), DC (anti-CD11c), and myeloid cells (macrophages [anti-Mac-1]).
b
Mice were conditioned with TCR/MR1/Rapa or MR1/Rapa
c
Mean ± SD percentage of donor cells in donor lymphoid gate.